Targeted diagnostics Ceres Nanosciences provides Nanotrap technology to improve sensitivity and accuracy across research and diagnostic platforms, presenting a ready-made opportunity to enhance current assay workflows for cancer, cardiac, and infectious disease biomarker detection.

Wastewater surveillance expansion Recent and ongoing funding from NIH RADx and partnerships in wastewater-based epidemiology indicate strong demand for scalable surveillance solutions; a strategic entry point for selling integrated Nanotrap-based sample prep to public health labs and wastewater testing networks.

Collaborative opportunities Past and present collaborations with Emory Healthcare, Biobot Analytics, and other research institutions demonstrate a track record of joint development; leverage these relationships to co-sell complementary Nanotrap products or custom workflow consulting.

Product portfolio lift New product launches such as Nanotrap Microbiome B Particles and Enhancement Reagent 3 suggest momentum in expanding the technology’s applications; align sales messaging to research labs and diagnostic centers seeking enhanced sample preparation for diverse assays.

SMB to mid-market fit With 11-50 employees and revenue in the low tens of millions, Ceres sits between niche biotech startups and larger diagnostics firms; pursue tiered offerings from pilot programs and custom kit bundles to larger scale licensing or collaboration deals.